The role of skin care and maintaining proper barrier function in the management of rosacea

Cosmetic Dermatology

Volumn 20, Issue 8, 2007, Pages 485-490

  Del Rosso, James Q ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF NEVADA   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c VALLEY HOSPITAL MEDICAL CENTER   (United States)

^d Galderma

^e OrthoNeutrogena ^*

^f Stiefel Laboratories Inc   (United States)

^g UNILEVER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; HUMECTANT; MACROLIDE; METRONIDAZOLE; SULFACETAMIDE; SULFACETAMIDE PLUS SULFUR; SULFUR; TETRACYCLINE; UNCLASSIFIED DRUG;

ACNE VULGARIS; ANTIMICROBIAL ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DEMODEX; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYGIENE; MONOTHERAPY; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SKIN CARE; SKIN TEST;

EID: 34548317390     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003;2:43-47.
2. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(suppl 3):28-31, 32-34.
3. Ichihashi M, Ueda M, Budiyanto A, et al. UV-induced skin damage. Toxicology. 2003;189:21-39.
4. Brenneisen P, Sies H, Scharffetter-Kochanek K. Ultraviolet-B irradiation and matrix metalloproteinases: from induction via signaling to initial events. Ann N Y Acad Sci. 2002;973:31-43.
5. Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis. 2004;73(suppl 1):5-8.
6. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100.
7. Powell FC. What's going on in rosacea? J Eur Acad Dermatol Venereol. 2000;14:351-352.
8. New study shows role for bacteria in development of rosacea symptoms [press release]. Providence, RI: National Rosacea Society; May 3, 2004.
9. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
10. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
11. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
12. Draelos ZD. Clinical situations conducive to proactive barrier enhancement. Cutis. 2002;70(suppl 6):17-20, 21-23.
13. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;74(suppl 3):21-27.
14. Del Rosso JQ. Medical management of rosacea with topical agents: a thorough appraisal of available treatment options and recent advances. Cosmet Dermatol. 2003;16:47-60.
15. Olansky S. Old drug - in a new system - revisited. Cutis. 1977;19:852-854.
16. Tarimci N, Sener S, Kilinc T. Topical sodium sulfacetamide/sulfur lotion. J Clin Pharm Ther. 1997;22:301.
17. Del Rosso JQ. A status report on medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
18. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282:449-454.
19. McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1:191-199.
20. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid 15% gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
21. Elewski B, Thiboutot D. A clinical overview of azelaic acid. Cutis. 2006;77(suppl 2):12-16.
22. Draelos ZD. The rationale for advancing the formulation of azelaic acid vehicles. Cutis. 2006;77(suppl 2):7-11.
23. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
24. Batyrshina SV, Gordeeva AM, Bogdanova MA, et al. Efficacy of Skinoren gel in the topical treatment of patients with acne vulgaris and rosacea [in Russian]. Vestnik Dermatologii I Venerologii. 2005;4:44-46.
25. Baranda L, Gonzalez-Amaro R, Torres-Alvarez B, et al. Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermatol. 2002;41:494-499.
26. Amblard P, Leccia MT. Skin diseases with photosensitivity [in French]. Rev Prat. 1992;42:1365-1368.
27. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.
28. Lavker RM, Veres DA, Irwin CJ, et al. Quantitative assessment of cumulative damage from repetitive exposures to suberythemogenic doses of UVA in human skin. Photochem Photobiol. 1995;62:348-352.
29. Lavker RM, Gerberick GF, Veres D, et al. Cumulative effects from repeated exposures to suberythemal doses of UVB and UVA in human skin. J Am Acad Dermatol. 1995;32:53-62.
30. Johnson AW. Overview: fundamental skin care - protecting the barrier. Dermatol Ther. 2004;17(suppl 1):1-5.
31. Ananthapadmanabhan KP, Moore DJ, Subramanyan K, et al. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther. 2004;17(suppl 1):16-25.
32. Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis. 2001;68(suppl 5):3-11.
33. Bikowski J. The use of cleansers as therapeutic concomitants in various dermatologic disorders. Cutis. 2001;68(suppl 5):12-19.
34. Del Rosso JQ. Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. Cutis. 2005;75(suppl 3):17-21, 33-36.
35. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(suppl 1):26-34.
36. Del Rosso JQ. Cutaneous tolerability of metronidazole topical gel 0.75% for rosacea. Cosmet Dermatol. 2005;18:559-562.
37. Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg. 2001;20:209-214.
38. Lippold BC. How to optimize drug penetration through the skin. Pharm Acta Helv. 1992;67:294-300.
39. New survey pinpoints leading factors that trigger symptoms [newsletter]. Providence, RI: National Rosacea Society; Summer 2002.
40. Murphy G. Ultraviolet light and rosacea. Cutis. 2004;74(suppl 3):13-16.
41. Hawkins SS, Subramanyan K, Liu D, et al. Cleansing, moisturizing, and sun-protection regiments for normal skin, self-perceived sensitive skin, and dermatologist-assessed sensitive skin. Dermatol Ther. 2004;17:63-68.
42. Draelos ZD, Green BA, Edison BL. An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. J Cosmet Dermatol. 2006;5:23-29.